{"id":"an2690-solution-7-5","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Dizziness"}]},"_chembl":{"chemblId":"CHEMBL3687053","moleculeType":"Small molecule","molecularWeight":"418.50"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This inhibition is thought to reduce pain by blocking the transmission of pain signals to the brain. AN2690 Solution, 7.5% has been investigated for its potential to treat various types of pain, including neuropathic pain.","oneSentence":"AN2690 Solution, 7.5% is a drug that works by inhibiting the activity of the sodium channel Nav1.8.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T04:09:08.200Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of neuropathic pain"}]},"trialDetails":[{"nctId":"NCT00680095","phase":"PHASE1","title":"Cumulative Irritation Test","status":"COMPLETED","sponsor":"Pfizer","startDate":"2007-01-22","conditions":"Onychomycosis","enrollment":37},{"nctId":"NCT00680160","phase":"PHASE2","title":"Absorption and Systemic Study of AN2690 in Patients With Moderate to Severe Onychomycosis (ADME I)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2006-04-30","conditions":"Onychomycosis","enrollment":15},{"nctId":"NCT00679965","phase":"PHASE2","title":"Study of Different Doses of a Novel Treatment for Onychomycosis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2006-02-28","conditions":"Distal, Subungual Onychomycosis","enrollment":159},{"nctId":"NCT01278394","phase":"PHASE2","title":"Safety and Efficacy Study of Subjects With Onychomycosis of the Great Toenail","status":"COMPLETED","sponsor":"Pfizer","startDate":"2007-03","conditions":"Onychomycosis","enrollment":29},{"nctId":"NCT00679523","phase":"PHASE2","title":"Safety and Efficacy Study of Subjects With Onychomycosis of the Great Toenail","status":"COMPLETED","sponsor":"Pfizer","startDate":"2005-11","conditions":"Onychomycosis","enrollment":60},{"nctId":"NCT00679770","phase":"PHASE2","title":"Study of Different Doses of a Novel Treatment for Onychomycosis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2006-06-30","conditions":"Distal, Subungual Onychomycosis","enrollment":28},{"nctId":"NCT00679601","phase":"PHASE2","title":"Absorption and Systemic Study of AN2690 in Patients With Moderate to Severe Onychomycosis (ADME II)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2007-03-31","conditions":"Onychomycosis","enrollment":20}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"AN2690 Solution, 7.5%","genericName":"AN2690 Solution, 7.5%","companyName":"Pfizer","companyId":"pfizer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AN2690 Solution, 7.5% is a drug that works by inhibiting the activity of the sodium channel Nav1.8. Used for Treatment of neuropathic pain.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}